Draft guidelines from the FDA on the electronic submission of data from clinical sites don't ensure that industry can rely on technical specifications to allow long-term planning, BIO said. The guidelines should address duplicative submissions that can delay site inspections, Pharmaceutical Research and Manufacturers of America said.

Related Summaries